NCT05242926View on ClinicalTrials.gov

Absorption and Excretion of Oral Docetaxel

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

June 30, 2018

Conditions
Solid Tumor, Adult
Interventions
DRUG

ModraDoc006/r

One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets

Trial Locations (1)

1066 CX

Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam

Sponsors
All Listed Sponsors
lead

Modra Pharmaceuticals

INDUSTRY

NCT05242926 - Absorption and Excretion of Oral Docetaxel | Biotech Hunter | Biotech Hunter